To Download a copy of the presentation click here.
To Download a copy of the Q&A Responses here.
*This call was funded by a cooperative agreement with the Centers for Disease Control and Prevention (grant number NU50CK000574). The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this call does not necessarily represent the policy of CDC or HHS, and should not be considered an endorsement by the Federal Government.
Moderator:
Dana S. Wollins, DrPH, MGC
Vice President, Clinical Affairs & Practice Guidelines, IDSA
Topics and Featured Experts:
Opening Remarks
Carlos del Rio, MD, FIDSA
IDSA President
Executive Associate Dean, Emory School of Medicine & Grady Health System
Distinguished Professor, Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine
Monkeypox Treatment Update
Jennifer R. Cope, MD, MPH
Captain, U.S. Public Health Service
Co-Lead, Clinical Escalations Team, Clinical Task Force
2022 Multinational Monkeypox Response
U.S. Centers for Disease Control & Prevention
Christina L. Hutson, PhD, MS
Laboratory and Testing Task Force Lead
2022 Multinational Monkeypox Response
Chief, Poxvirus and Rabies Branch
U.S. Centers for Disease Control & Prevention
SARS-CoV-2 Subvariants & the Future of Monoclonal Antibodies
Update on Emerging SARS-CoV-2 Subvariants
Natalie J. Thornburg, PhD
Respiratory Virus Immunology Team Lead
Division of Viral Diseases
National Center for Immunization and Respiratory Diseases
U.S. Centers for Disease Control and Prevention
Impact of SARS-CoV-2 Subvariants on Therapeutic Effectiveness
Rajesh T. Gandhi, MD, FIDSA
Director, HIV Clinical Services and Education
Massachusetts General Hospital
Co-Director, Harvard Center for AIDS Research
Professor of Medicine, Harvard Medical School
William A. Werbel, MD
Assistant Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University
Robert W. Shafer, MD
Professor of Medicine
Division of Infectious Diseases
Stanford University
Meghan E. Pennini, PhD
Therapeutics Director
Administration for Strategic Preparedness and Response
U.S. Department of Health and Human Services
